Vacuum-Assisted Biopsy A Good Option For Fast Breast Tissues Clinical Assessment
CT-Guided VAB outperforms prone stereotactic biopsy for fastest breast tissues biopsy.
When sampling breast tissue, research shows CT-guided vacuum-assisted biopsy is faster than using prone stereotactic vacuum-assisted biopsy (VAB). In a retrospective study, published in the American Journal of Roentgenology, researchers analyzed VAB results on women with mammographically-suspicious breast lesions using dedicated breast cone beam CT (CBCT) protocol. They assessed and compared technical success rates, total intervention time, and complications with CT-guided VAB and prone stereotactic VAB. Between June 2015 and March 2016, 65 patients with 68 lesions underwent image-guided VAB. Twenty-nine patients with 31 lesions had CT-guided VAB. Prone stereotactic VAB was performed on 36 patients with 37 lesions. Technical success rate occurs in 31 of 33 lesions (93.9%) with CT VAB and 37 of 38 lesions (97.9%) with prone stereotactic VAB. Mean total intervention time was 22.7 +/-8.4 minutes for CT-guided VAB and 28.8 +/- 9.4 minutes for prone stereotactic VAB. Neither system had major complications. According to researchers, time to reidentifying and target lesions took about the same time, but tissue sampling is significantly faster with CT-guided VAB, making it more clinically feasible.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
